| Literature DB >> 28397814 |
Li-Kuo Liu1,2, Chao-Yu Guo1,3, Wei-Ju Lee1,4, Liang-Yu Chen1,2,3, An-Chun Hwang1,2,3, Ming-Hsien Lin1,2, Li-Ning Peng1,2,3, Liang-Kung Chen1,2, Kung-Yee Liang1,3.
Abstract
Frailty is a well-recognized geriatric syndrome with various definitions and conceptual frameworks. This study aimed to use latent class analysis to discover potential subtypes of pre-frail and frail older people. Data from the I-Lan Longitudinal Aging Study (ILAS), a community-based cohort study was used for analysis. Latent class analysis was applied to characterize classes or subgroups with different frailty phenotypes among ILAS participants targeting older adults aged 65 and above, capable of completing a 6-meter walk, without severe major or life threatening diseases, and not institutionalized. Latent class analysis identified three distinct subgroups with different frailty phenotypes: non-mobility-type (weight loss and exhaustion), mobility-type frailty (slowness and weakness), and low physical activity. Comparing these groups with the robust group, people with mobility-type frailty had poorer body composition, worse bone health, poorer cognitive function, lower survival (hazard ratio: 6.82, p = 0.019), and poorer overall health outcomes (hazard ratio: 1.67, p = 0.040). People in the non-mobility-type group had poorer bone health and more metabolic serum abnormalities. In conclusion, mobility-type frailty was a better predictor of adverse outcomes. However, further investigation is needed to evaluate how these phenotypic subgroups may help in predicting prognosis or in developing interventions.Entities:
Mesh:
Year: 2017 PMID: 28397814 PMCID: PMC5387710 DOI: 10.1038/srep46417
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Frailty-defining criteria in ILAS and CHS.
| Characteristics | ILAS | % | CHS | ||||
|---|---|---|---|---|---|---|---|
| Definition | Definition | % | |||||
| Weight loss | Lost >5 kg (5%) unintentionally in last year, or Lost >3 kg unintentionally within 3 months | 5.3 | Lost >10 lbs unintentionally in last year | 7.3 | |||
| Exhaustion | As for CHS | 4.0 | Self-report of either of: (i) felt that everything I did was an effort in the last week, or (ii) could not get going in the last week | 21.3 | |||
| Low physical activity | The lowest gender-specific 20% of study population (IPAQ score) | 20.0 | A version of the Minnesota Leisure Time Activities Questionnaire | 24.1 | |||
| Women < 270 | Men < 383 | ||||||
| Slowness | Walking 6 meters: The lowest gender-specific 20% of study population | 23.6 | Time to walk 15 feet (4.57 m) | 38.0 | |||
| Women | Men | ||||||
| ≤159 cm high | >159 cm high | ≤173 cm high | >173 cm high | ||||
| ≥7 s | ≥6 s | ≥7 s | ≥6 s | ||||
| Weakness | Grip strength: The lowest gender-specific 20% of study population | 21.6 | Grip strength (kg) | 26.2 | |||
| Women | Men | ||||||
| BMI ≤ 23 | ≤17 kg | BMI ≤ 24 | ≤29 kg | ||||
| BMI 23.1–26 | ≤17.3 kg | BMI 24.1–28 | ≤30 kg | ||||
| BMI 26.1–29 | ≤18 kg | ||||||
| BMI > 29 | ≤21 kg | BMI > 28 | ≤32 kg | ||||
| Robust | 52.7 | Robust | 33.2 | ||||
| Pre-frail | 40.5 | Pre-frail | 55.2 | ||||
| Frail | 6.8 | Frail | 11.6 | ||||
ILAS, The I-Lan Longitudinal Aging Study; CHS, Cardiovascular Health Study; BMI, body mass index (kg/m2); IPAQ, International Physical Activity Questionnaire.
Frailty Criteria Patterns and Latent Class Analysis Fit: ILAS.
| Parameter estimates | Measurement items (in order): Weight loss/Exhaustion/Low activity/slowness/weakness | Observed count | Pattern frequncies expected | ||
|---|---|---|---|---|---|
| Criterion: No (N) or Yes (Y) | 2-Class Model | 3-Class Model | 4-Class Model | ||
| 6 Most frequently observed nonfrail patterns | NNNNN | 970 | 1023.7 | 1097.8 | 1066.4 |
| NNYNN | 166 | 170.2 | 185.7 | 193.0 | |
| NNNYN | 144 | 141.7 | 120.8 | 95.3 | |
| NNNNY | 141 | 143.4 | 135.1 | 121.3 | |
| NNNYY | 100 | 76.3 | 81.6 | 86.7 | |
| NNYYN | 47 | 46.1 | 42.1 | 39.8 | |
| 6 Most frequently observed frail patterns | NNYYY | 73 | 52.2 | 58.9 | 70.1 |
| NYYYY | 10 | 7.7 | 10.2 | 10.7 | |
| NYNYY | 9 | 9.9 | 8.5 | 8.5 | |
| NYYYN | 9 | 4.8 | 7.3 | 9.6 | |
| YNNYY | 7 | 6.2 | 7.0 | 4.2 | |
| NYYNY | 4 | 2.3 | 3.6 | 3.5 | |
| Pearson chi square | 27.7 (p < 0.0001) | 12.2 (p = 0.007) | 5.1 (p = 0.274) | ||
| AIC | 6840 | 6837 | 6843 | ||
| BIC | 6901 | 6930 | 6970 | ||
ILAS, The I-Lan Longitudinal Aging Study; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.
Conditional Probabilities of Meeting Criteria Within Latent Frailty Classes: ILAS*.
| Rho estimate | 3-class model | 4-class model | |||||
|---|---|---|---|---|---|---|---|
| Class 1 (Non-frail) | Class 2 | Class 3 | Class 1 | Class 2 (Non-frail) | Class 3 | Class 4 | |
| Class prevalence (%) | 55.5 | 25.0 | 19.5 | 3.6 | 55.4 | 15.8 | 25.3 |
| Weight loss | 0.0257 | 0.1072 | 0.0600 | 0.1030 | 0.0148 | 0.0532 | 0.1284 |
| Exhaustion | 0.0190 | 0.0003 | 0.1494 | 0.2007 | 0.0201 | 0.1350 | 0.0004 |
| Low physical activity | 0.1633 | 0.0152 | 0.5402 | 0.8851 | 0.1592 | 0.4657 | 0.0250 |
| Slowness | 0.0048 | 0.3499 | 0.7497 | 0.2427 | 0.0078 | 0.9442 | 0.2930 |
| Weakness | 0.0593 | 0.2749 | 0.5898 | 0.4362 | 0.0930 | 0.6130 | 0.2081 |
ILAS, The I-Lan Longitudinal Aging Study. *Per class and criterion: Estimated proportion in class exhibiting the criterion.
Comparisons between different groups based on LCA.
| Variable | Robust | Non-mobility group | Mobility group† | Low activity | p-value |
|---|---|---|---|---|---|
| Number | 970 | 61 | 385 | 166 | |
| Age (years) | 60.7 ± 7.5 | 61.5 ± 7.2 | 69.0 ± 8.9 | 60.9 ± 7.9 | <0.001 |
| Sex (male %) | 45.8 | 45.9 | 52.2 | 46.4 | 0.193 |
| Smoking (%) | 16.6 | 23.0 | 19.0 | 18.7 | 0.095 |
| WC (cm) | 83.8 ± 9.4 | 85.8 ± 9.5 | 85.9 ± 10.1 | 84.5 ± 9.9 | 0.004 |
| BMI (kg/m2) | 24.8 ± 3.5 | 25.2 ± 3.8 | 24.8 ± 3.7 | 25.1 ± 3.5 | 0.569 |
| Total body fat (%) | 31.5 ± 8.7 | 31.6 ± 9.6 | 31.0 ± 8.8 | 32.9 ± 7.2 | 0.133 |
| ASM (kg) | 18.3 ± 4.3 | 18.6 ± 4.4 | 17.3 ± 3.7 | 18.1 ± 4.1 | <0.001 |
| Hip T-score | −0.66 ± 1.04 | −0.86 ± 1.14 | −1.15 ± 1.09 | −0.67 ± 1.03 | <0.001 |
| SMAF | −0.01 ± 0.15 | 0.0 ± 0.0 | −0.11 ± −0.68 | −0.01 ± 0.08 | <0.001 |
| MMSE | 26.8 ± 3.0 | 26.5 ± 3.0 | 24.2 ± 4.0 | 26.8 ± 3.4 | <0.001 |
| CES-D | 1.5 ± 2.6 | 4.5 ± 6.0 | 2.3 ± 3.6 | 1.7 ± 3.0 | <0.001 |
| MNA-SF | 13.4 ± 0.8 | 12.9 ± 1.6 | 13.4 ± 0.9 | 13.6 ± 0.8 | <0.001 |
| CCI | 0.7 ± 1.1 | 0.9 ± 1.2 | 1.4 ± 1.4 | 0.7 ± 1.0 | <0.001 |
| Hypertension (%) | 34.64 | 37.70 | 50.13 | 39.76 | <0.001 |
| Diabetes (%) | 13.40 | 18.03 | 19.74 | 15.66 | 0.031 |
| Dyslipidemia (%) | 6.19 | 16.39 | 11.17 | 6.02 | 0.001 |
| Albumin (mg/dl) | 4.6 ± 0.2 | 4.5 ± 0.3 | 4.4 ± 0.3 | 4.6 ± 0.2 | <0.001 |
| HbA1c (%) | 6.0 ± 0.9 | 6.2 ± 1.5 | 6.1 ± 1.0 | 6.1 ± 1.2 | 0.012 |
| LDL-cholesterol (mg/dl) | 120.3 ± 32.6 | 132.5 ± 33.4 | 114.8 ± 31.0 | 118.3 ± 33.8 | <0.001 |
| HDL-cholesterol (mg/dl) | 55.8 ± 13.9 | 53.1 ± 14.5 | 53.6 ± 13.1 | 54.0 ± 13.6 | 0.030 |
| Creatinine (mg/dl) | 0.8 ± 0.3 | 0.8 ± 0.4 | 0.8 ± 0.2 | 0.9 ± 0.5 | 0.371 |
| hs-CRP (mg/dl) | 0.2 ± 0.4 | 0.2 ± 0.3 | 0.2 ± 0.5 | 0.2 ± 0.4 | 0.221 |
| Growth hormone (ng/ml) | 0.8 ± 1.4 | 0.9 ± 1.4 | 0.6 ± 1.1 | 0.8 ± 1.2 | 0.131 |
| Free Androgen Index (%) | 17.4 ± 18.9 | 19.8 ± 22.6 | 17.2 ± 16.7 | 17.9 ± 19.0 | 0.780 |
| DHEA-S (μg/dl) | 113.4 ± 71.1 | 101.2 ± 57.3 | 91.9 ± 60.2 | 119.9 ± 74.7 | <0.001 |
| IGF-1 (ng/ml) | 144.3 ± 57.7 | 145.6 ± 51.5 | 119.8 ± 49.7 | 144.5 ± 60.4 | <0.001 |
| 25(OH)D (ng/ml) | 23.1 ± 6.5 | 23.3 ± 6.0 | 25.2 ± 8.5 | 21.3 ± 6.1 | <0.001 |
*Non-mobility group: participants with weight loss, exhaustion or both. †Mobility group: participants with weakness, slowness or both. WC, waist circumference; BMI, body mass index; ASM, appendicular skeletal muscle mass; SMAF, the Functional Autonomy Measurement System; MMSE, Mini-Mental State Examination; CES-D, the Center for Epidemiologic Studies Depression Scale; MNA-SF, Mini-nutrition assessment-short form; CCI, Charlson Comorbidity Index; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high-sensitive C-reactive protein; DHEA-S, dehydroepiandrosterone sulfate; IGF-1, insulin-like growth factor-1; 25(OH)D, 25-hydroxyvitamin D.
Cox proportional hazard ratios for times until death and until other poor health outcomes: ILAS.
| Frail state | Poor health Outcomes | ||||
|---|---|---|---|---|---|
| Number/death n | Death | Total | |||
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Robust | 970/2 | 1.00 (reference) | 1.00 (reference) | ||
| Non-mobility group* | 61/0 | N/A | 0.988 | 1.00 (0.31–3.25) | 0.999 |
| Mobility group† | 385/6 | 6.82 (1.37–33.85) | 0.019 | 1.67 (1.02–2.74) | 0.040 |
| Low activity | 166/1 | 3.76 (0.34–41.60) | 0.281 | 0.71 (0.25–1.99) | 0.514 |
| Non-mobility + Low activity | 14/0 | N/A | 0.994 | 1.55 (0.21–11.27) | 0.667 |
| Mobility + Low activity | 154/5 | 17.16 (3.33–88.51) | 0.001 | 2.67 (1.47–4.84) | 0.001 |
*Non-mobility group: participants with weight loss, exhaustion or both. †Mobility group: participants with weakness, slowness or both. HR, hazard ratio; CI, confidence interval, ILAS, The I-Lan Longitudinal Aging Study; N/A, not available.
Figure 1Kaplan-Meier survival curves for different subgroup in ILAS participants by LCA analysis.